Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs NS 065 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors NS Pharma
- 20 Dec 2016 Status changed from not yet recruiting to recruiting.
- 28 Nov 2016 Planned initiation date changed from 1 Jul 2016 to 1 Dec 2016.
- 12 Apr 2016 Status changed from planning to not yet recruiting.